73 completed, 6 active not recruiting, 6 unknown, 4 withdrawn. 95 Phase 2, 19 Phase 1, 7 Phase 3.
Follow Streptococcal Infections: new trials by email Literature Review of Streptococcal Infections trials Research Report on Streptococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial GBS-NN/NN2 vaccine, Placebo - Streptococcus Agalactiae Infection, Neonatal Sepsis | Phase 2 / Phase 3 | Not yet recruiting | Minervax ApS | 6600 | 2026-11-30 | 2026-11-06 |
| Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M), PCV24 vaccine (dose H), PCV24 vaccine (dose M) - Streptococcus Pneumoniae Infection | Phase 1 / Phase 2 | Recruiting | CanSino Biologics Inc. | 854 | 2026-05-24 | 2026-08-05 |
| Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years Sinovac PCV24, Prevnar® - Pneumococcal Infectious Disease | Phase 2 | Recruiting | Sinovac Life Sciences Co., Ltd. | 420 | 2025-11-25 | 2025-12-24 |
| Clinical Trial Phase I/IIa to Evaluate the Safety and Immunogenicity of StreptInCor StrepIncor, Placebo - Rheumatic Heart Disease, Rheumatic Heart Disease in Children | Phase 1 / Phase 2 | Not yet recruiting | University of Sao Paulo General Hospital | 60 | 2025-10-01 | 2025-07-22 |
| PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700), 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13) - Pneumococcal Infectious Disease | Phase 2 | Completed | Reinovax Biologics Co., LTD | 480 | 2025-09-11 | 2026-07-27 |
| Clinical Trial of PCV24 in Adults Aged ≥18 Years Sinovac Low-dosage PCV24, Sinovac Middle-dosage PCV24, Sinovac High-dosage PCV24 - Pneumococcal Infectious Disease | Phase 1 / Phase 2 | Completed | Sinovac Life Sciences Co., Ltd. | 385 | 2025-06-18 | 2026-04-21 |
| A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women GBS-NN/NN2 vaccine - Streptococcus Agalactiae Infection, Neonatal Sepsis | Phase 2 / Phase 3 | Active not recruiting | Minervax ApS | 137 | 2025-03-07 | 2026-09-04 |
| Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants Formulation B, Formulation C, Formulation D - Pneumococcal Disease, Invasive | Phase 2 | Active not recruiting | Inventprise Inc. | 421 | 2025-01-27 | 2025-09-02 |
| GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age GBS-NN/NN2 vaccine, Tdap vaccine, Placebo - Streptococcus Agalactiae Infection | Phase 2 / Phase 3 | Withdrawn | Minervax ApS | 2024-12-17 | 2026-10-13 | |
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31 - Pneumococcal Vaccines | Phase 2 | Active not recruiting | Vaxcyte, Inc. | 900 | 2024-11-25 | 2026-05-15 |
| Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age. IVT GBS-06, Placebo - Group B Streptococcal Infections | Phase 1 / Phase 2 | Active not recruiting | Inventprise Inc. | 600 | 2024-11-12 | 2025-11-18 |
| A Study to Learn About How a New Pneumococcal Vaccine Works in Children PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease | Phase 2 | Completed | Pfizer | 225 | 2024-07-30 | 2026-03-11 |
| A Study to Learn About How a New Pneumococcal Vaccine Works in Infants PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15) - Pneumococcal Disease | Phase 2 | Active not recruiting | Pfizer | 605 | 2024-07-25 | 2026-11-06 |
| Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, Reinovax PCV24 formulation 3 - Pneumococcal Infectious Disease | Phase 2 | Completed | Reinovax Biologics Co., LTD | 992 | 2024-04-20 | 2026-08-17 |
| A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease | Phase 1 / Phase 2 | Completed | Pfizer | 1710 | 2023-12-20 | 2026-11-06 |
| A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers mPnC candidate, mPnC control - Healthy Participants | Phase 2 | Completed | Pfizer | 105 | 2023-11-08 | 2025-05-08 |
| GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial phenoxymethyl penicillin, intramuscular benzathine penicillin G (BPG) prophylaxis - Rheumatic Heart Disease | Phase 2 | Active not recruiting | Children's Hospital Medical Center, Cincinnati | 1004 | 2023-09-01 | 2026-10-19 |
| Extension Safety and Immunogenicity Study of GPNV-001 Gamma-PN3, Pneumovax-23, Prevenar-13 - Pneumococcal Infections | Phase 1 / Phase 2 | Completed | GPN Vaccines | 60 | 2023-07-17 | 2024-12-18 |
| Painless Sharp Wound Debridement With Lidocaine-23%-Tetra-caine-7% Gel Versus EMLA 5% Cream IMP2 (lidocaine-23%-tetracaine-7% gel), IMP1 (EMLA 5% cream) - Ulcus Cruris, Ecthyma | Phase 2 | Unknown | Juerg Hafner | 40 | 2023-06-01 | 2023-06-06 |
| Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24 - Pneumococcal Vaccines | Phase 2 | Completed | Vaxcyte, Inc. | 802 | 2023-03-29 | 2025-09-11 |
Showing 20 of 95. Sign in to see all of them.
Pneumococcal Infections (43) · Impetigo (9) · Pneumonia (8) · Cellulitis (5) · Pneumonia, Pneumococcal (5) · Rheumatic Heart Disease (5) · Bacterial Infections (4) · Haemophilus Infections (4) · Abscess (3) · Endocarditis, Subacute Bacterial (3) · Erysipelas (3) · Gram-Positive Bacterial Infections (3) · Infections (3) · HIV Infections (2)
Bacterial Infections and Mycoses (94) · Gram-Positive Bacterial Infections (92) · Infections (92) · Bacterial Infections (91) · Skin and Connective Tissue Diseases (17) · Skin Diseases (14) · Skin Diseases, Bacterial (14) · Skin Diseases, Infectious (14) · Lung Diseases (13) · Respiratory Tract Diseases (13) · Respiratory Tract Infections (12) · Staphylococcal Infections (11) · Cardiovascular Diseases (10) · Pathological Conditions, Signs and Symptoms (10)
13-valent pneumococcal vaccine (23) · Pneumococcal Vaccines (8) · 23-valent pneumococcal capsular polysaccharide vaccine (7) · Heptavalent Pneumococcal Conjugate Vaccine (6) · PHiD-CV vaccine (5) · Vaccines, Combined (4) · Saline Solution (3) · Sodium Chloride (3) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (3) · CRM197 (non-toxic variant of diphtheria toxin) (2) · Daptomycin (2) · Penicillin G (2) · 10-valent pneumococcal conjugate vaccine (1) · Alprostadil (1) · Blood Specimen Collection (1)
GlaxoSmithKline (11) · Pfizer (10) · Merck Sharp & Dohme LLC (8) · Minervax ApS (5) · Assistance Publique - Hôpitaux de Paris (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Inventprise Inc. (2) · LEO Pharma (2) · Lytix Biopharma AS (2) · NovaBay Pharmaceuticals, Inc. (2) · Novartis Vaccines (2) · PATH (2) · Reinovax Biologics Co., LTD (2) · Sinovac Life Sciences Co., Ltd. (2) · Vaxcyte, Inc. (2)
United States (33) · South Africa (9) · China (6) · Canada (5) · Czechia (4) · Denmark (4) · France (4) · Puerto Rico (4) · Uganda (4) · Australia (3) · Belgium (3) · Germany (3) · Poland (3) · Spain (3) · Dominican Republic (2)
Cornelia Oostvogels (2) · Philippe Prokocimer, MD (2) · Adriana Weinberg, MD (1) · Almena L Free, MD (1) · Amar Safdar, MD (1) · Andrea Beaton, MD (1) · Andrea Z Beaton (1) · Benjamin Rossi, MD (1) · Daisy M Blanco, MD (1) · Daisy M. Blanco, MD (1)
PMID 30689507, PMID 15882530, PMID 17391816, PMID 18470901, PMID 18799552, PMID 20199764, PMID 20206670, PMID 20435707, PMID 20943882, PMID 21044669, PMID 21537018, PMID 21539882, PMID 22353593, PMID 23300160, PMID 23535358, PMID 23967126, PMID 25496504, PMID 26409812, PMID 26869376, PMID 26942345, PMID 27139805, PMID 27530088, PMID 28917688, PMID 29029127, PMID 29279281, PMID 29374589, PMID 29559167, PMID 30244873, PMID 30427749, PMID 30648919, PMID 31301533, PMID 31843266, PMID 32169390, PMID 32639460, PMID 32716500, PMID 32891191, PMID 33186665, PMID 33661716, PMID 33767093, PMID 34525007, PMID 34767321, PMID 35690500, PMID 36116461, PMID 37307310, PMID 37491088, PMID 37927075, PMID 38141728, PMID 38190492, PMID 38360475, PMID 38797460
2023 (3), 2009 (1), 2014 (1), 2016 (1), 2018 (1), 2019 (1), 2025 (1), R01DA048892 (1), U10HD021364 (1), U10HD021385 (1), U10HD027880 (1), U10HD034216 (1), U10HD036790 (1), U10HD040492 (1), U10HD040689 (1)